Lukas Biomedical Inc. (TPEX:6814)
Taiwan
· Delayed Price · Currency is TWD 27.20
+0.70 (2.64%)
Mar 10, 2026, 1:21 PM CST
Lukas Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | 180.32 | 189.83 | 231.83 | 184.79 | 157.62 | 181.41 | Upgrade
|
| Revenue Growth (YoY) | -16.12% | -18.12% | 25.46% | 17.24% | -13.11% | 18.66% | Upgrade
|
| Cost of Revenue | 73.82 | 76.71 | 97.94 | 86.88 | 61.56 | 62.96 | Upgrade
|
| Gross Profit | 106.51 | 113.12 | 133.89 | 97.91 | 96.06 | 118.45 | Upgrade
|
| Selling, General & Admin | 108.91 | 110.32 | 100.12 | 90.55 | 85.33 | 89.73 | Upgrade
|
| Research & Development | 91.72 | 94.73 | 77.33 | 55.92 | 54.98 | 35.39 | Upgrade
|
| Other Operating Expenses | - | - | - | - | - | -0.01 | Upgrade
|
| Operating Expenses | 200.84 | 205.25 | 177.45 | 146.37 | 139.13 | 123.75 | Upgrade
|
| Operating Income | -94.33 | -92.14 | -43.56 | -48.47 | -43.06 | -5.3 | Upgrade
|
| Interest Expense | -2.82 | -3.04 | -3.07 | -2.92 | -4.42 | -4.83 | Upgrade
|
| Interest & Investment Income | 0.49 | 0.46 | 0.09 | 0.07 | 0.04 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.13 | -0.01 | -1 | 1 | -0.14 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.21 | 0.25 | 0.47 | -0.83 | 0.71 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -96.33 | -94.47 | -47.07 | -51.14 | -46.86 | -10.08 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | - | -0.47 | 1.02 | -1.21 | 0.11 | Upgrade
|
| Other Unusual Items | 0 | - | 0.26 | 0.2 | 0.24 | - | Upgrade
|
| Pretax Income | -96.32 | -94.47 | -47.28 | -49.92 | -47.83 | -9.96 | Upgrade
|
| Income Tax Expense | -0.1 | -0.1 | 0.08 | 0.15 | 1.66 | 0.59 | Upgrade
|
| Earnings From Continuing Operations | -96.22 | -94.38 | -47.35 | -50.07 | -49.49 | -10.54 | Upgrade
|
| Net Income | -96.22 | -94.38 | -47.35 | -50.07 | -49.49 | -10.54 | Upgrade
|
| Net Income to Common | -96.22 | -94.38 | -47.35 | -50.07 | -49.49 | -10.54 | Upgrade
|
| Shares Outstanding (Basic) | 42 | 40 | 37 | 37 | 33 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 40 | 37 | 37 | 33 | 33 | Upgrade
|
| Shares Change (YoY) | 13.00% | 7.34% | 0.27% | 11.87% | - | - | Upgrade
|
| EPS (Basic) | -2.30 | -2.38 | -1.28 | -1.36 | -1.51 | -0.32 | Upgrade
|
| EPS (Diluted) | -2.30 | -2.38 | -1.28 | -1.36 | -1.51 | -0.32 | Upgrade
|
| Free Cash Flow | -87.99 | -77.35 | -14.41 | -10.41 | -26.18 | 22.39 | Upgrade
|
| Free Cash Flow Per Share | -2.10 | -1.95 | -0.39 | -0.28 | -0.80 | 0.68 | Upgrade
|
| Gross Margin | 59.06% | 59.59% | 57.75% | 52.98% | 60.95% | 65.29% | Upgrade
|
| Operating Margin | -52.31% | -48.54% | -18.79% | -26.23% | -27.32% | -2.92% | Upgrade
|
| Profit Margin | -53.36% | -49.72% | -20.42% | -27.10% | -31.40% | -5.81% | Upgrade
|
| Free Cash Flow Margin | -48.80% | -40.75% | -6.21% | -5.63% | -16.61% | 12.34% | Upgrade
|
| EBITDA | -82.3 | -77.85 | -26.3 | -25.63 | -18.68 | 21.96 | Upgrade
|
| EBITDA Margin | -45.64% | -41.01% | -11.34% | -13.87% | -11.85% | 12.11% | Upgrade
|
| D&A For EBITDA | 12.03 | 14.28 | 17.26 | 22.83 | 24.38 | 27.26 | Upgrade
|
| EBIT | -94.33 | -92.14 | -43.56 | -48.47 | -43.06 | -5.3 | Upgrade
|
| EBIT Margin | -52.31% | -48.54% | -18.79% | -26.23% | -27.32% | -2.92% | Upgrade
|
| Advertising Expenses | - | 40.26 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.